The DOI matches its Crossref record.
Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder
Open accessAbstract
Dysfunction of glutamatergic neurotransmission may be relevant to the pathogenesis of post-traumatic stress disorder (PTSD). Preclinical and clinical evidence suggests that PTSD symptoms could be alleviated following enhancement of neurotransmission mediated at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Eleven patients with chronic PTSD participated in a double-blind, placebo-controlled, cross-over trial with 50 mg/d D-cycloserine which acts as a partial agonist at the glycine regulatory site on the NMDA receptor. D-cycloserine treatment resulted in significant improvements in numbing, avoidance, and anxiety symptoms; however, similar effects were also observed during placebo treatment. In addition, D-cycloserine treatment resulted in a significant (p=0.03), reduction in the perseverative error scores as measured by the Wisconsin Card Sorting Test. This pilot study is the first to assess the efficacy of a NMDA receptor modulator for PTSD treatment and its results warrant further, larger-scale investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This, considered collectively with findings from animal studies, leads to the postulation that DCS administration without extinction training cannot facilitate fear extinction.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Heresco-Levy et al, 2002
In the citing paper
“On the other hand, studies reported by Heresco-Levy et al (2002) did not demonstrate sufficient efficacy for DCS in the treatment of PTSD (Heresco-Levy et al, 2002).”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Heresco-Levy et al (2002)
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 18
- Bouton ME, Bulles RC (1985). Contexts, event memories and extinction. In: Balsam PDD, Tomick A (Eds.), Context and Learning (pp. 133-166). Hillside NJ: Lawrence Erlbaum Associates.
- Davidson JRT (1997). Biological therapies for posttraumatic stress disorder: an overview. Journal of Clinical Psychiatry 58 (Suppl. 9), 29-32.
- Davidson JRT (2000). Pharmacotherapy of posttraumatic stress disorder : treatment option, long-term follow-up and predictors of outcome. Journal of Clinical Psychiatry 61 (Suppl. 5), 52-56.
- Friedman MJ (1988). Current and future drug treatment for posttraumatic stress disorder patients. Psychiatric Annals 28, 461-468.
- Friedman MJ (2000). What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy. Journal of Clinical Psychiatry 61 (Suppl. 7), 44-51.
- Glue P, Nutt DY, Coupland NJ (1993). Stress and psychiatric disorder : reconciling social and biological approaches. In : Stanford SC, Salmon P (Eds.), Stress: An Integrated Approach (pp. 53-73). London: Academic Press.
- Goff DC, Tsai G, Manoach DS, Coyle JT (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry 152, 1213-1215.
- Hamilton M (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 175, 17-22.
- Hamilton M (1960). A rating scale for depression. Journal of Neurological and Neurosurgical Psychiatry 23, 56-62.
- Heresco-Levy U (2000). N-methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia : the first decade. International Journal of Neuropsychopharmacology 3, 243-258.
- Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine or risperidone in schizophrenia. American Journal of Psychiatry 159, 480-482.
- Jones RW, Wesnes KA, Kirby J (1991). Effects of NMDA modulation in scopolamine dementia. Annals of the New York Academy of Science 640, 241-244.
- Kessler RB (2000). Posttraumatic Stress Disorder: the burden to the individual and to society. Journal of Clinical Psychiatry 61 (Suppl. 5), 4-12.
- Marshall RD, Davidson JRT, Yehuda R (1998). Pharmacotherapy in the treatment of posttraumatic stress disorder and other trauma-related syndromes. In : Yehuda R (Ed.), Psychological Trauma, Review of Psychiatry, vol. 17 (pp. 133-177). Washington, DC : American Psychiatric Press.
- McAllister WR, McAllister DE (1998). Reconditioning of extinguished fear after a one-year delay. Bulletin of the Psychonomic Society 26, 463-466.
- Nutt DJ (2000). The psychobiology of posttraumatic stress disorder. Journal of Clinical Psychiatry 61 (Suppl. 5), 24-32.
- Vakil E, Blachstein H (1993). Rey Auditory-Verbal Learning Test: structure analysis. Journal of Clinical Psychology 49, 883-890.
- Vreven DL, Gudanowski DM, King LA, King DW (1995). The civilian version of the Mississippi PTSD scale: a psychometric evaluation. Journal of Trauma and Stress 8, 91-109.
Cited by
Sorted by citations
Response Variation following Trauma: A Translational Neuroscience Approach to Understanding PTSD
Yehuda, R., & LeDoux, J. E. (2007) · Neuron · doi:10.1016/j.neuron.2007.09.006 · Cited by 841
Glutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 534
“001 11.7 0.001 13 0.001 186 Tsai et al (1999) DSER Clozapine 20 2.5 NS 0.8 NS 3.6 NS 98 Goff et al (1999) DCS Conventional 47 23 o.02c — — — NS 187 Heresco-Levy et al (2002) DCS Mixed 21a 14 o.05 — — — NS 188 Goff et al (1999) DCS Clozapine 17a þ 13d o.005 — — — NS 189 —¼not determined; NS¼not…”
InfluentialSelf-citationPharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“Although not known to be efficacious as a monotherapy (149), DCS at a low dose of 50 mg/day (which is largely anNMDA agonist) has been successfully used in augmentation of exposure therapy or CBT, including reducing anxiety in persons performing cognitive tasks (150) and facilitating declarative learning (151) by redu…”
MethodSingewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“…short CBT sessions (Litz et al., 2012), insufficient within-session fear inhibition (Smits et al., 2013b; Tart et al., 2013), chronic DCS treatment (Heresco-Levy et al., 2002), DCS administration outside the therapeutic temporal window (Storch et al., 2007) and subclinical levels of fear…”
Background
Metadata
- Authors
- Heresco-Levy, U., Kremer, I., Javitt, D. C., Goichman, R., Reshef, A., Blanaru, M., & Cohen, T.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- Nathan Kline Institute for Psychiatric Research (US)
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-12
- Volume
- 5
- Issue
- 4
- Pages
- 301-307
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W4213356598
- Cited by
- 134
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 8 · 2016: 10 · 2015: 5 · 2014: 11 · 2013: 4 · 2012: 10
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
- Keywords
- D-cycloserine, post-traumatic stress disorder, NMDA receptor modulation, glutamatergic neurotransmission, chronic PTSD, Wisconsin Card Sorting Test, avoidance symptoms, anxiety symptoms, numbing symptoms
- MeSH terms
- Adult, Antibiotics, Antitubercular, Chronic Disease, Cognition, Cycloserine, Double-Blind Method, Female, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Stress Disorders, Post-Traumatic, Receptors, Glycine, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
